Are All Anti-Angiogenic Drugs the Same in the Treatment of Second-Line Metastatic Colorectal Cancer? Expert Opinion on Clinical Practice

Overview

Journal Front Oncol

Specialty Oncology

Date 2021 May 27

PMID 34041019

Citations 9

Authors

Eleonora Lai

Stefano Cascinu

Mario Scartozzi

Affiliations

Soon will be listed here.

Abstract

Targeting tumor-driven angiogenesis is an effective strategy in the management of metastatic colorectal cancer (mCRC); however, the choice of second-line therapy is complicated by the availability of several drugs, the occurrence of resistance and the lack of validated prognostic and predictive biomarkers. This review examines the use of angiogenesis-targeted therapies for the second-line management of mCRC patients. Mechanisms of resistance and anti-placental growth factor agents are discussed, and the role of aflibercept, a recombinant fusion protein consisting of portions of human vascular endothelial growth factor receptor (VEGFR)-1 and VEGFR-2, is highlighted. The novel mechanism of action of aflibercept makes it a useful second-line agent in mCRC patients progressing after oxaliplatin-based chemotherapy, as well as in those with resistance after bevacizumab.

Citing Articles

Characterization and validation of a prognostic model for the N6-methyladenosine-associated ferroptosis gene in colon adenocarcinoma.

Liu X, An J, Wang Q, Jin H Transl Cancer Res. 2024; 13(8):4389-4407.

PMID: 39262465 PMC: 11384320. DOI: 10.21037/tcr-24-88.

Multi-Omics analysis elucidates tumor microenvironment and intratumor microbes of angiogenesis subtypes in colon cancer.

Yang Y, Qiu Y, Li W, Cui Z, Teng S, Wang Y World J Gastrointest Oncol. 2024; 16(7):3169-3192.

PMID: 39072166 PMC: 11271793. DOI: 10.4251/wjgo.v16.i7.3169.

Editorial: Angiogenesis and access to vasculature as a target in gastrointestinal tumors and predictive biomarkers identification: an open challenge.

Lai E, Ziranu P, Pezzella F, Pretta A, Liscia N, Hu Z Front Oncol. 2024; 14:1428174.

PMID: 38832255 PMC: 11145327. DOI: 10.3389/fonc.2024.1428174.

Prediction of Response to Anti-Angiogenic Treatment for Advanced Colorectal Cancer Patients: From Biological Factors to Functional Imaging.

Corrias G, Lai E, Ziranu P, Mariani S, Donisi C, Liscia N Cancers (Basel). 2024; 16(7).

PMID: 38611042 PMC: 11011199. DOI: 10.3390/cancers16071364.

Diatom-Based Nanomedicine for Colorectal Cancer Treatment: New Approaches for Old Challenges.

Tramontano C, De Stefano L, Rea I Mar Drugs. 2023; 21(5).

PMID: 37233460 PMC: 10222510. DOI: 10.3390/md21050266.

References

Giampieri R, Ziranu P, Daniele B, Zizzi A, Ferrari D, Lonardi S . From CENTRAL to SENTRAL (SErum aNgiogenesis cenTRAL): Circulating Predictive Biomarkers to Anti-VEGFR Therapy. Cancers (Basel). 2020; 12(5). PMC: 7281010. DOI: 10.3390/cancers12051330. View

Chau I, Fakih M, Garcia-Alfonso P, Linke Z, Ruiz Casado A, Polo Marques E . Safety and Effectiveness of Aflibercept + Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) for the Treatment of Patients with Metastatic Colorectal Cancer (mCRC) in Current Clinical Practice: OZONE Study. Cancers (Basel). 2020; 12(3). PMC: 7139359. DOI: 10.3390/cancers12030657. View

Aravantinos G, Isaakidou A, Karantanos T, Sioziou A, Theodoropoulos G, Pektasides D . Association of CD133 polymorphisms and response to bevacizumab in patients with metastatic colorectal cancer. Cancer Biomark. 2015; 15(6):843-50. DOI: 10.3233/CBM-150528. View

Muro K, Salinardi T, Singh A, Macarulla T . Safety of Aflibercept in Metastatic Colorectal Cancer: A Literature Review and Expert Perspective on Clinical and Real-World Data. Cancers (Basel). 2020; 12(4). PMC: 7225956. DOI: 10.3390/cancers12040844. View

Petracci E, Scarpi E, Passardi A, Biggeri A, Milandri C, Vecchia S . Effectiveness of bevacizumab in first- and second-line treatment for metastatic colorectal cancer: ITACa randomized trial. Ther Adv Med Oncol. 2020; 12:1758835920937427. PMC: 7378711. DOI: 10.1177/1758835920937427. View

Lu C, Lin J, Chen W, Lin T, Jiang J, Yang S . Intraperitoneal ziv-aflibercept effectively manages refractory ascites in colorectal cancer patients. Oncotarget. 2016; 8(22):36707-36715. PMC: 5482690. DOI: 10.18632/oncotarget.13543. View

Feliu J, Diez de Corcuera I, Manzano J, Valladares-Ayerbes M, Alcaide J, Garcia Garcia T . Effectiveness and safety of aflibercept for metastatic colorectal cancer: retrospective review within an early access program in Spain. Clin Transl Oncol. 2016; 19(4):498-507. DOI: 10.1007/s12094-016-1556-3. View

Horita Y, Yamada Y, Kato K, Hirashima Y, Akiyoshi K, Nagashima K . Phase II clinical trial of second-line FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: AVASIRI trial. Int J Clin Oncol. 2011; 17(6):604-9. DOI: 10.1007/s10147-011-0331-2. View

Hamaguchi T, Denda T, Kudo T, Sugimoto N, Ura T, Yamazaki K . Exploration of potential prognostic biomarkers in aflibercept plus FOLFIRI in Japanese patients with metastatic colorectal cancer. Cancer Sci. 2019; 110(11):3565-3572. PMC: 6825011. DOI: 10.1111/cas.14198. View

10.

Parisi A, Cortellini A, Cannita K, Venditti O, Camarda F, Calegari M . Evaluation of Second-line Anti-VEGF after First-line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter "SLAVE" Study. Cancers (Basel). 2020; 12(5). PMC: 7281759. DOI: 10.3390/cancers12051259. View

11.

Venook A, Niedzwiecki D, Lenz H, Innocenti F, Fruth B, Meyerhardt J . Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial. JAMA. 2017; 317(23):2392-2401. PMC: 5545896. DOI: 10.1001/jama.2017.7105. View

12.

Stintzing S, Modest D, Rossius L, Lerch M, Fischer von Weikersthal L, Decker T . FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial. Lancet Oncol. 2016; 17(10):1426-1434. DOI: 10.1016/S1470-2045(16)30269-8. View

13.

Zhao L, Wang J, Li H, Che J, Cao B . Meta-analysis comparing maintenance strategies with continuous therapy and complete chemotherapy-free interval strategies in the treatment of metastatic colorectal cancer. Oncotarget. 2016; 7(22):33418-28. PMC: 5078106. DOI: 10.18632/oncotarget.8644. View

14.

Martins S, Reis R, Rodrigues A, Baltazar F, Longatto Filho A . Role of endoglin and VEGF family expression in colorectal cancer prognosis and anti-angiogenic therapies. World J Clin Oncol. 2011; 2(6):272-80. PMC: 3139037. DOI: 10.5306/wjco.v2.i6.272. View

15.

Gonzalez-Vacarezza N, Alonso I, Arroyo G, Martinez J, de Andres F, LLerena A . Predictive biomarkers candidates for patients with metastatic colorectal cancer treated with bevacizumab-containing regimen. Drug Metab Pers Ther. 2016; 31(2):83-90. DOI: 10.1515/dmpt-2015-0027. View

16.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

17.

Ivanova J, Saverno K, Sung J, Duh M, Zhao C, Cai S . Real-world treatment patterns and effectiveness among patients with metastatic colorectal cancer treated with ziv-aflibercept in community oncology practices in the USA. Med Oncol. 2017; 34(12):193. PMC: 5671551. DOI: 10.1007/s12032-017-1049-4. View

18.

Giantonio B, Catalano P, Meropol N, ODwyer P, Mitchell E, Alberts S . Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007; 25(12):1539-44. DOI: 10.1200/JCO.2006.09.6305. View

19.

Denda T, Sakai D, Hamaguchi T, Sugimoto N, Ura T, Yamazaki K . Phase II trial of aflibercept with FOLFIRI as a second-line treatment for Japanese patients with metastatic colorectal cancer. Cancer Sci. 2019; 110(3):1032-1043. PMC: 6398889. DOI: 10.1111/cas.13943. View

20.

Yoshino T, Arnold D, Taniguchi H, Pentheroudakis G, Yamazaki K, Xu R . Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. Ann Oncol. 2017; 29(1):44-70. DOI: 10.1093/annonc/mdx738. View